The Arestat™ reformulation technology platform consists of a patented series of over ten different mechanistically defined families of specific combinations of excipients which, when selected and combined with a therapeutic medicine, will deliver novel formulations with enhanced properties that would otherwise be unachievable.

Arestat™ results in improved product formats with enhanced properties ranging from greater safety and convenience through to superior therapeutic profiles which can improve patient care and health outcomes. It can be applied to a broad range of products, notably antibodies, complex biologics, peptides and vaccines.

Development of the formulations with enhanced properties using the Arestat™ technology follows four key steps:

  •  

    Examples of Arestat™-enhanced, superior product profiles that are otherwise achievable include:

    • Liquid products with superior stability

    → Use outside the cold chain, improved shelf-life

    • Lyophilised powder to liquid switch

    → Convenient liquid product to replace lyophilised compositions requiring complex reconstitution

    • High concentration products for subcutaneous administration

    → Low viscosity, low rate of aggregation

    • Ready-to-use (RTU) and ready-to-administer (RTA) formats

    → For example, stable liquid concentrates for intravenous (IV) administration or pre-mixed IV bags

    • Control of absorption from subcutaneous injection site

    → Improved pharmacokinetic/ pharmacodynamic (PK/PD) profiles

    Learn More